News
Press Releases
SolasCure announces final closing of GBP 10.9m (c. USD 13.3m) Series B fundraise to advance wound care innovation
Funding will support the development of Aurase Wound Gel and progress towardfurther Phase II clinical trials of innovative wound debriding enzyme Cambridge, UK 27 March
SolasCure named a UK Life Sciences Innovator 2023 by the UK’s Department for International Trade
SolasCure, a Cambridge-based biotech company developing revolutionary wound-cleaningtechnology, has been named a UK Life Sciences Innovator in a showcase sponsored by the UK’sDepartment for International Trade.
SolasCure announces publication of toxicology and pre-clinical research programme as final patient is enrolled into pivotal clinical trial
Innovative Cambridge biotech company SolasCure, which is developing a revolutionarywound cleaning technology, has published its pre-clinical results with the InternationalWound Journal, showing preliminary evidence that
SolasCure’s David Fairlamb recognised at TOPRA Awards for exceptional leadership in regulatory strategy
David Fairlamb, Director of Regulatory Affairs at SolasCure, has been named as a winner at the TOPRA awards. The awards, organised by The Organisation for
SolasCure wins 1st place at prestigious EIT Health Catapult biotech competition for investigational wound care product Aurase Wound Gel
SolasCure has been named the winner of the biotech category at the EIT Health Catapult finals in Stockholm. The medical use of Aurase Wound Gel
Cambridge biotech company earns international recognition as first trial patient receives treatment
SolasCure, a Cambridge-based biotech company developing revolutionary wound-cleaning technology, has seen its first trial patient receive treatment. Leveraging biomimicry and evidence-based medicine, the pioneering biologics
Biotech start-up SolasCure has begun clinical trials of its investigational wound cleaning product, Aurase Wound Gel
Cambridge-based biologics company SolasCure has received authorisation to conduct clinical trials for its investigational product, Aurase Wound Gel, from the UK’s Medical and Healthcare products
SolasCure announces £15m Series A raise
Biotech start-up SolasCure has announced the completion of its Series A investment round, to support the development of its wound cleaning product, Aurase. The Cambridge
Thought Leadership
Harnessing the power of maggots: Cambridge biologics company SolasCure is developing an accessible method for cleaning chronic wounds, inspired by nature’s solution
Maggot therapy, the unpleasant practice of introducing living fly larvae into wounds to remove dead and dying tissue, is astonishingly effective. Its popularity can be
Treating Chronic Wounds Effectively: The Unmet Need
After more than 20 years in the life sciences industry, Dr. Sam Bakri, Executive Chairman and CEO of biotech start-up, SolasCure shares his journey as
Seneca Partners invests £1.2m into biotech start-up SolasCure
18 AUGUST 2021
The Biomimicry Institute's AskNature: Improved Wound Debridement Using Maggot Enzymes
Aurase is an investigational product containing maggot enzymes that aims to help remove dead…
11 AUGUST 2021
6 Ireland-UK start-ups ready for the Catapult Semifinals
24 JUNE 2021
A Truly Revolting Treatment Is Having a Renaissance
2 JUNE 2021
Startup Solascure chosen for the URGO Mentorship Program
URGO Group announces the winner of its 2019 URGO Mentorship Program: SolasCure, a Wales-based biotech…
09 SEPTEMBER 2019
BRAIN Biotech AG announces the creation of SolasCure Ltd. to continue development of Aurase
22 AUGUST 2018
BRAIN AG announces the creation of SolasCure Ltd. to continue development of Aurase®
BRAIN is providing IP and fully integrating their development programme for biological wound care based on the Aurase® enzyme…
Startup Solascure chosen for the URGO Mentorship Program
URGO Group announces the winner of its 2019 URGO Mentorship Program: SolasCure, a Wales-based biotech which has developed an innovative wound care solution…
News
News Press Releases Thought Leadership External Media Coverage Seneca Partners invests £1.2m into biotech start-up SolasCure Seneca Partners (Seneca), the specialist SME investment business based
